US Launches Investigation into Drug Prices in Germany, Risking Renewed Tensions with Europe

The United States government has initiated a formal investigation into Germany's pharmaceutical pricing policies, alleging that the country’s healthcare system systematically underpays for innovative medicines. This move by the Trump administration aims to address claims that European price regulations force pharmaceutical companies to charge higher prices in the U.S. market to recoup research and development costs. For the pharmaceutical sector, this escalation signals a significant shift in trade relations that could impact global pricing strategies and market access across the European Union.

On June 19, the office of the U.S. Trade Representative announced the launch of an investigation to determine if Germany’s persistent underpayment for innovative drugs is unreasonable or discriminatory and restricts U.S. commerce. This action comes just days after the European Parliament approved a trade agreement on June 16 intended to stabilize relations between the 27 member states and the U.S. The investigation specifically targets the German healthcare system's regulatory framework, which Washington argues places an unfair burden on American consumers and businesses.

U.S. President Donald Trump and Health Secretary Robert Kennedy Jr. have positioned this investigation as a necessary step to lower domestic drug costs. The administration contends that because European governments regulate and cap drug prices, pharmaceutical manufacturers are forced to seek higher profit margins in the United States to fund the development of new treatments. For the past 18 months, Washington has pressured European nations to increase their drug spending, a demand that the EU member states have consistently resisted.

The investigation threatens to undermine the Turnberry agreement of July 2025, which was designed to guarantee that tariffs on European products sold in the U.S. would not exceed 15%. By labeling Germany's pricing practices as unreasonable, the White House could justify imposing additional surcharges on German exports, effectively bypassing previous trade guarantees. This development creates a new lever of pressure on the broader European Union, potentially forcing a confrontation over how innovative therapies are valued and reimbursed in international markets.